Royal DSM N.V. (RDSMY.PK), a life and material science company, reported the completion of the acquisition of a 19% interest in Yantai Andre Pectin Co. Ltd., a China-based producer of texturing ingredients.
Previously, DSM had purchased a 10% stake in Andre Pectin from Hony Capital. DSM's total shareholding in Andre Pectin is currently 29%. The parties agreed that DSM has option rights to increase its stake in Andre Pectin to a majority stake at a later stage.
DSM said its investment in Andre Pectin, synergistically combined with the prior acquired China-based gellan gum assets, creates a China-based hydrocolloids growth platform, in line with its strategy for the Nutrition cluster, continued value growth.
For comments and feedback contact: editorial@rttnews.com
Business News
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.